Kurashiki, Japan

Chie Fujiwara

This inventor holds 1 USPTO granted patent. Top assignee: Kuraray Co., Ltd.. Active years: 1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chie Fujiwara. Retrieved from https://idiyas.com/inventor/chie-fujiwara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chie Fujiwara: Innovator in Peptide Technology

Introduction

Chie Fujiwara is a notable inventor based in Kurashiki, Japan. He has made significant contributions to the field of peptide technology, particularly in the development of peptides with high binding activity for human interleukin-1.

Latest Patents

Chie Fujiwara holds 1 patent for his invention titled "Peptide or its salts." This patent focuses on peptides that exhibit high binding activity for human interleukin-1, represented by a specific formula.

Career Highlights

Fujiwara is associated with Kuraray Co., Ltd., a company known for its innovative materials and technologies. His work at Kuraray has allowed him to explore and develop advanced peptide solutions that have potential applications in various medical fields.

Collaborations

Chie Fujiwara has collaborated with notable colleagues, including Tatsuo Suda and Etsuko Abe. Their combined expertise has contributed to the advancement of peptide research and development.

Conclusion

Chie Fujiwara's work in peptide technology exemplifies the innovative spirit of modern science. His contributions continue to pave the way for advancements in medical research and applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…